Understanding the mechanisms of treatment resistance in colorectal cancer using organoid models

MRC · United Kingdom government procurement

GlobalGov surfaces government procurement from around the world, including the markets your competitors overlook.

April 29, 2028
Response Due
Active
Status

Opportunity Overview

Colorectal (bowel) cancer affects more than 45,000 people in the UK each year, and only about 50-60% of people treated for bowel cancer survive 5 years after being diagnosed. One of the ways to improve the survival of patients with bowel cancer is by giving chemo and/or radiotherapy to shrink the cancer down before any surgery is carried out. This is known as "neoadjuvant therapy" and has been used a lot for patients with cancer affecting the last bit of the bowel (the back passage). It has only recently been found in a research study called FOXTROT that it may be effective in patients with cancer in other parts of the bowel (the colon) as well.

Despite these advances, this type of treatment only leads to substantial shrinkage of the cancer in approximately 10-20% of patients. We would like to improve this, as in patients where a lot of shrinkage occurs they do much better than patients who do not get any shrinkage. I have carried out research in cancer of the back passage that shows two potential ways we could increase the shrinkage by giving two different, very new, drug therapies in addition to the standard treatment.

We have found this by making "mini-avatars" called organoids, which are cancers grown in the laboratory from a specimen of the patient's cancer. These undergo exactly the same response to treatment in the laboratory as the patient would experience when their cancer is treated.
I would like to expand the research I have done by growing more models of colon cancer, and then using them to simulate neoadjuvant treatment and then analyse them using genetic sequencing. This will allow us to understand what makes them resistant to treatment, and then identify new treatments (chosen by expert oncologists) that may make them more sensitive. We can then re-treat the resistant models with these new drugs to see if they work.Through this, we hope to further increase the benefit of treatment given before surgery to patients, increasing...

This is one of 1,833 active United Kingdom Research Development opportunities most of your competitors will never see.

Your competitors are watching the same crowded contracts everyone else is. Track this opportunity and every one like it worldwide, set deadline alerts, and win where they aren’t. Free for 14 days, no card.

Start Free

Solicitation Details

Issuing agencyMRC
CountryUnited Kingdom
CategoryResearch Development
PublishedApril 30, 2023
Procurement stageActive solicitation
Response dueApril 29, 2028
StatusOpen — accepting responses
Official sourceView original notice
Last verifiedAugust 09, 2026

Source: UK Research and Innovation (UKRI) — Open Government Licence v3.0.

Related Opportunities in United Kingdom

The systems neuroscience of Human Memory and its Disorders
Mendelian Randomisation
Integrating polygenic risk scores with clinical drug development
Adaptive processing of spoken language: flexible communication in health, disease and disorder
Project to be confirmed after rotation year
Molecular mechanisms of dynein-2 activation and transport in cilia
Mental Health Neuroscience Programme
Adaptation and Feasibility assessment of a primary suicide prevention intervention for school adolescents in Nigeria

See every United Kingdom Research Development opportunity your competition is missing. Free for 14 days.

Get real-time alerts, competitive intelligence, and deadline tracking for this and every market worldwide.

Start Free Trial — No Card Required

Free 14-day trial · no card required

See who is already competing here →

Get a free United Kingdom Research Development intelligence report in your inbox

A personalized report on United Kingdom Research Development opportunities, emailed in 5-10 minutes. One per month, no account needed.